Comparing recovery after adrenal surgery with and without drainage tubes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the safety and effectiveness of tubeless laparoscopic adrenalectomy compared to traditional methods that use drainage tubes. It aims to determine how the absence of drainage affects recovery times, pain levels, and overall postoperative outcomes in patients undergoing adrenal surgery. Participants will be randomly assigned to either a tubeless or drainage group, with various recovery metrics monitored over time. The study will recruit 200 patients and follow them closely to assess their recovery progress.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. According to the 2022 edition of the Chinese Guidelines for Diagnosis and Treatment of Urological Diseases, patients who meet the surgical indications
2. The patient has signed an informed consent form before joining the clinical trial, and the age at the time of signing the informed consent form is 18-70 years old.

Exclusion Criteria:

1. Patients with complications that seriously affect treatment or quality of life
2. The patient has any physical condition that the researcher believes will affect the clinical status
3. Patients who have placed vascular stents such as heart and cerebrovascular stents within the past year
4. Pregnant or lactating patients

Where it's running

• Zhongnan hospital
  Wuhan, Hubei, China Recruiting

Study contacts

• Principal investigator: meng zhe — Wuhan University
• Study coordinator: meng zhe
• Email: mengzhe@whu.edu.cn
• Phone: 15387041020

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Kidney stiffness measured by ultrasound in hypertension and healthy volunteers

  This study tests whether kidney stiffness measured by a non-invasive ultrasound method differs between people with high blood pressure and healthy individuals.

  Recruiting Azienda Ospedaliera di Padova · Padova, PD · NCT07914075

• Inclisiran vs. Statin for Primary Aldosteronism

  This trial tests whether inclisiran plus amlodipine works differently from a statin-based approach in people with primary aldosteronism and high blood pressure.

  Recruiting Third Military Medical University · Chongqing, Chongqing Municipality · NCT07884955

• Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities

  This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.

  Recruiting University Hospital Augsburg · Augsburg, Bavaria · NCT07857044

• Metomidate PET-CT vs Usual Care for Primary Aldosteronism

  This study tests whether [11C] metomidate PET-CT can help orient treatment for people with primary aldosteronism compared with the usual adrenal venous sampling approach.

  Recruiting Chinese University of Hong Kong · Shatin · NCT07814105

• Myokines in metabolic and endocrine diseases linked to sarcopenia

  This study tests whether myokines can serve as biomarkers or drivers of sarcopenia and sarcopenic obesity in people with metabolic or endocrine diseases.

  Recruiting Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Woluwe-Saint-Pierre - Sint-Pieters-Woluwe · NCT07703683

• Captopril Test with LC-MS/MS for Aldosterone and Renin in Primary Aldosteronism

  This study tests whether measuring aldosterone with LC-MS/MS during a captopril test can better diagnose primary aldosteronism.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07691801

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.